SLC5A2 and heart failure: Collectively, the reduction in the primary composite endpoint in the two HFmrEF and HFpEF patients was mainly driven by a markedly lower risk of hospitalization for heart failure, while cardiovascular deaths in both trials were not substantially reduced in the SGLT2 inhibitor treatment group.